Maryland Capital Management bought a new position in shares of Iqvia Holdings Inc (NYSE:IQV) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 160,691 shares of the medical research company’s stock, valued at approximately $15,731,000. Iqvia makes up 2.3% of Maryland Capital Management’s investment portfolio, making the stock its 15th biggest holding.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Winslow Evans & Crocker Inc. bought a new stake in Iqvia during the 4th quarter worth approximately $123,000. Valeo Financial Advisors LLC bought a new stake in Iqvia during the 4th quarter worth approximately $170,000. IFP Advisors Inc bought a new stake in Iqvia during the 4th quarter worth approximately $200,000. Livforsakringsbolaget Skandia Omsesidigt bought a new stake in Iqvia during the 4th quarter worth approximately $209,000. Finally, Atria Investments LLC bought a new stake in Iqvia during the 4th quarter worth approximately $218,000. 96.09% of the stock is owned by institutional investors and hedge funds.
A number of analysts recently issued reports on IQV shares. TheStreet raised Iqvia from a “c+” rating to a “b” rating in a research note on Wednesday, December 13th. Zacks Investment Research raised Iqvia from a “hold” rating to a “buy” rating and set a $112.00 target price for the company in a research note on Thursday, January 18th. Royal Bank of Canada set a $118.00 target price on Iqvia and gave the stock a “buy” rating in a research note on Thursday, February 15th. ValuEngine raised Iqvia from a “hold” rating to a “buy” rating in a research note on Tuesday, February 20th. Finally, Mizuho set a $97.00 target price on Iqvia and gave the stock a “hold” rating in a research note on Wednesday, January 24th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. Iqvia has an average rating of “Buy” and a consensus target price of $110.02.
Iqvia (NYSE:IQV) last issued its quarterly earnings results on Wednesday, February 14th. The medical research company reported $1.32 earnings per share for the quarter, missing the consensus estimate of $1.34 by ($0.02). The business had revenue of $2.16 billion for the quarter, compared to the consensus estimate of $2.14 billion. Iqvia had a return on equity of 13.03% and a net margin of 13.44%. Iqvia’s revenue was up 10.7% compared to the same quarter last year. During the same period in the prior year, the business earned $1.09 earnings per share. equities research analysts predict that Iqvia Holdings Inc will post 3.29 earnings per share for the current fiscal year.
In other news, insider James H. Erlinger III sold 10,000 shares of the stock in a transaction that occurred on Wednesday, January 17th. The stock was sold at an average price of $99.97, for a total value of $999,700.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Ari Bousbib sold 46,080 shares of the stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $101.79, for a total value of $4,690,483.20. The disclosure for this sale can be found here. Insiders have sold a total of 76,080 shares of company stock valued at $7,702,283 over the last ninety days. Company insiders own 6.40% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Maryland Capital Management Takes Position in Iqvia Holdings Inc (IQV)” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3230865/maryland-capital-management-takes-position-in-iqvia-holdings-inc-iqv.html.
IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.